Wednesday, November 4, 2026
Guggenheim kept its Buy rating on Spyre Therapeutics (SYRE) and raised its price target to $135 from $130.
Wedbush kept its Outperform rating on Spyre Therapeutics (SYRE) and lowered its price target to $120 from $123.
Monday, October 19, 2026
BTIG kept its Buy rating on Spyre Therapeutics (SYRE).
Monday, October 12, 2026
UBS started coverage of Spyre Therapeutics (SYRE) with a Buy rating and a price target of $120.
Thursday, October 1, 2026
J.P. Morgan started coverage of Spyre Therapeutics (SYRE) with an Overweight rating and a price target of $110.
Wednesday, September 9, 2026
Wedbush kept its Outperform rating on Spyre Therapeutics (SYRE).
Wednesday, August 26, 2026
Deutsche Bank kept its Buy rating on Spyre Therapeutics (SYRE) and lowered its price target to $127 from $135.
Wedbush kept its Outperform rating on Spyre Therapeutics (SYRE) and lowered its price target to $123 from $130.
BTIG kept its Buy rating on Spyre Therapeutics (SYRE) and lowered its price target to $121 from $132.
Frequently asked questions
What is the latest news on SYRE?
Nov 4, 2026: Guggenheim kept its Buy rating on Spyre Therapeutics (SYRE) and raised its price target to $135 from $130. (Guggenheim) · Nov 4, 2026: Wedbush kept its Outperform rating on Spyre Therapeutics (SYRE) and lowered its price target to $120 from $123. (Wedbush) · Oct 19, 2026: BTIG kept its Buy rating on Spyre Therapeutics (SYRE). (BTIG)
What are analysts saying about SYRE?
Nov 4, 2026: Guggenheim kept its Buy rating on Spyre Therapeutics (SYRE) and raised its price target to $135 from $130. · Nov 4, 2026: Wedbush kept its Outperform rating on Spyre Therapeutics (SYRE) and lowered its price target to $120 from $123. · Oct 19, 2026: BTIG kept its Buy rating on Spyre Therapeutics (SYRE).
Get SYRE news as it happens
Every headline, SEC filing and analyst action for SYRE on your live chart, with important news marked and alerts when it matters.
Try SEPT Free